Considerations in the treatment of mild-to-moderate hypertension.
作者信息
Giaquinta D
出版信息
Manag Care Interface. 2001 Mar;14(3):80-1.
PMID:11301960
Abstract
摘要
相似文献
1
Considerations in the treatment of mild-to-moderate hypertension.
Manag Care Interface. 2001 Mar;14(3):80-1.
2
Improving prescribing practices in primary care. A randomised trial and economic analysis of a multicomponent intervention showed small, but important, gains.改善基层医疗中的处方行为。一项多组分干预措施的随机试验和经济分析显示，虽成效不大，但却意义重大。
PLoS Med. 2006 Jun;3(6):e229. doi: 10.1371/journal.pmed.0030229.
3
[Investigation and treatment of primary hypertension].[原发性高血压的调查与治疗]
Lakartidningen. 2008;105(30-31):2107-12.
4
Health economic issues and the future treatment and management of hypertension.
AAPPO J. 1994 Jul-Aug;4(4):27-8, 30, 33-5.
5
Drug therapy of cardiovascular risk factors: guidelines versus reality in primary health care service.心血管危险因素的药物治疗：初级卫生保健服务中的指南与现实
Croat Med J. 2005 Dec;46(6):984-9.
6
[Research and marketing].[研究与营销]
Tidsskr Nor Laegeforen. 2004 Jul 1;124(13-14):1820.
7
8
Economics of drug treatment.药物治疗经济学
Lancet. 2002 Mar 9;359(9309):892-3. doi: 10.1016/S0140-6736(02)07935-7.
9
An economic evaluation of the 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of mild-to-moderate hypertension in Greece.2003年欧洲高血压学会-欧洲心脏病学会希腊轻度至中度高血压管理指南的经济学评估。
Am J Hypertens. 2005 Sep;18(9 Pt 1):1233-40; discussion 1241-2. doi: 10.1016/j.amjhyper.2005.05.001.
10
Discrepancies between use of antihypertensive drugs and guidelines indications: pharmacoeconomic implications.抗高血压药物使用与指南适应症之间的差异：药物经济学影响。
J Hum Hypertens. 2005 Oct;19(10):819-22. doi: 10.1038/sj.jhh.1001900.
Zotero 插件